The cobas Mass Spec solution Ionify reagent portfolio now covers therapeutic drug monitoring for immunosuppressants and antibiotics
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
The sale/transfer of the Company's API NonAntibiotic Business and API Antibiotic Business to Apitoria are complete
Subscribe To Our Newsletter & Stay Updated
